Raymond Anderson

CIK: 0001362489

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (42.9%)

Position reduction

Option Exercises (M)2 (28.6%)

Derivative conversions

Awards (A)2 (28.6%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

MNPR

Monopar Therapeutics

Director

Discretionary Trading P&L

Holdings

Transaction History (7 total)

MNPR
Monopar Therapeutics
Aug 25, 2026
Exercise(M)
Direct
1.4K shares at avg. $30.00$42K
MNPR
Monopar Therapeutics
Aug 25, 2026
Exercise(M)
Direct
1.7K shares at avg. $30.00$52K
MNPR
Monopar Therapeutics
Aug 25, 2026
Sale(S)
Direct
694 shares at avg. $110.04$76K
MNPR
Monopar Therapeutics
Aug 25, 2026
Sale(S)
Direct
646 shares at avg. $111.07$72K
MNPR
Monopar Therapeutics
Aug 25, 2026
Sale(S)
Direct
1.8K shares at avg. $113.05$204K
MNPR
Monopar Therapeutics
Dec 2, 2025
Award(A)
Stock Options
Direct
2.9K shares-
MNPR
Monopar Therapeutics
Mar 4, 2025
Award(A)
Stock Options
Direct
11.4K shares-

		Type	Shares	Price		Ownership
Aug 25, 2026	MNPR Monopar Therapeutics	Exercise(M)	1,402	$30.00	$42,060	Direct
Aug 25, 2026	MNPR Monopar Therapeutics	Exercise(M)	1,740	$30.00	$52,200	Direct
Aug 25, 2026	MNPR Monopar Therapeutics	Sale(S)	694	$110.04	$76,368	Direct
Aug 25, 2026	MNPR Monopar Therapeutics	Sale(S)	646	$111.07	$71,751	Direct
Aug 25, 2026	MNPR Monopar Therapeutics	Sale(S)	1,802	$113.05	$203,716	Direct
Dec 2, 2025	MNPR Monopar Therapeutics	Award(A) Stock Options	2,924	-	-	Direct
Mar 4, 2025	MNPR Monopar Therapeutics	Award(A) Stock Options	11,365	-	-	Direct

1-7 of 7 transactions

About Anderson Raymond

Anderson Raymond (SEC CIK 0001362489) files insider reports with the SEC as Director of Monopar Therapeutics (MNPR).

Signal8 holds 4 ownership filings by Anderson Raymond, all Form 4s, filed between Mar 7, 2025 and Aug 28, 2026. Those filings report 7 transactions, from Mar 4, 2025 to Aug 25, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Anderson Raymond's filings is in WILMETTE, IL.

Recent filings by Anderson Raymond

Aug 25, 2026: Option exercises of MNPR shares (2 lines, Form 4, code M).
Aug 25, 2026: Open-market sales of MNPR shares (3 lines, Form 4, code S).
Dec 2, 2025: Grant or award of MNPR derivative securities (Form 4, code A).
Mar 4, 2025: Grant or award of MNPR derivative securities (Form 4, code A).

Other insiders filing for Monopar Therapeutics (MNPR)

Robinson Chandler, Chief Executive Officer
STARR CHRISTOPHER M, Director
Cittadine Andrew, Chief Operating Officer
Vu Quan Anh, Chief Financial Officer
Tsuchimoto Kim R, Director
RIOUX PATRICE, Officer

How to read Form 4 transaction codes